NCT04121767View on ClinicalTrials.gov

Safety and Efficacy of Edoxaban in Thoracoscopic Ablation

NACompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

December 1, 2017

Primary Completion Date

June 30, 2020

Study Completion Date

July 10, 2020

Conditions
Atrial FibrillationAnticoagulants and Bleeding Disorders
Interventions
DRUG

Edoxaban

oral edoxaban 60mg once daily for 3 months

DRUG

Warfarin

oral warfarin once daily for 3 months according to prothrombin time

Trial Locations (1)

135-710

Samsung Medical Center, Seoul

All Listed Sponsors
lead

Samsung Medical Center

OTHER

NCT04121767 - Safety and Efficacy of Edoxaban in Thoracoscopic Ablation | Biotech Hunter | Biotech Hunter